# Strategic Vision: Command & Control for Cancer Warfare

**Date:** December 23, 2025  
**Status:** ‚úÖ **VALIDATED** - TRUE SAE AUROC 0.783 beats PROXY 0.628  
**Location:** `.cursor/MOAT/SAE_INTELLIGENCE/06_STRATEGIC_VISION.md`  
**See Also:** [00_MISSION.mdc](00_MISSION.mdc), [03_GENERALS_BATTLE_MAP.mdc](03_GENERALS_BATTLE_MAP.mdc)

---

## üî• THE BREAKTHROUGH: TRUE SAE IS REAL

### **What We Proved:**

After months of extraction, validation failures, pivots, and persistence:

| Discovery | Value | Evidence |
|-----------|-------|----------|
| **TRUE SAE AUROC** | 0.783 ¬± 0.100 | 5-fold CV, 149 patients |
| **PROXY SAE AUROC** | 0.628 ¬± 0.119 | Same cohort, same folds |
| **DELTA** | +0.155 | TRUE SAE wins ALL 5 folds |
| **DDR_bin p-value** | 0.0020 | Mann-Whitney U |
| **Cohen's d** | 0.642 | Medium-large effect |

### **The DDR_bin Discovery:**

All 9 "diamond" features map to **DNA Damage Repair pathway**:
- TP53 dominates (28/30 top variants per feature)
- Biological coherence: platinum resistance = DDR restoration
- **Steerability V1 is now possible**: DDR_bin as intervention surface

### **Publication Status:**
- ‚úÖ Manuscript draft complete
- ‚úÖ Figures 2, 3, 4 generated
- ‚úÖ References compiled
- üéØ Target: bioRxiv preprint ‚Üí Nature Methods

---

## üéØ THE STRATEGIC VISION: CANCER WARFARE INTELLIGENCE

### **What We're Building:**

A Command & Control system that:
1. **PREDICTS** resistance before it happens (TRUE SAE)
2. **DETECTS** pathway changes in real-time (DDR_bin, MAPK_bin)
3. **INTERVENES** with mechanism-aligned treatments (Steerability)
4. **MONITORS** for escape mechanisms (Resistance Prophet)

This is **proactive oncology**, not reactive.

---

## üöÄ EXPANSION BEYOND NF1: PAN-CANCER ROADMAP

### **Phase 1: Ovarian Cancer (COMPLETE)**

| Marker | Status | Evidence |
|--------|--------|----------|
| NF1 ‚Üí MAPK resistance | ‚úÖ Skeptic | RR=2.10, p<0.05 |
| DDR_bin features | ‚úÖ Skeptic | 9 features, AUROC 0.783 |
| TRUE SAE > PROXY | ‚úÖ PROVED | ŒîAUROC = +0.155 |

### **Phase 2: Multiple Myeloma (PROXY VALIDATED)**

| Marker | Status | Evidence |
|--------|--------|----------|
| DIS3 mortality | ‚úÖ Skeptic | RR=2.08, p=0.0145 |
| TP53 mortality | ‚ö†Ô∏è TREND | RR=1.90, p=0.11 |
| TRUE SAE extraction | ‚è≥ PENDING | Need MMRF data |

**Plumber Task:** Download MMRF CoMMpass from GDC, extract TRUE SAE features, run head-to-head.

### **Phase 3: Pan-Cancer Expansion**

| Cancer | Data Source | Key Pathways | Predicted Bins |
|--------|-------------|--------------|----------------|
| **Lung (NSCLC)** | TCGA-LUAD | EGFR, ALK, KRAS | EGFR_bin, MAPK_bin |
| **Breast (TNBC)** | TCGA-BRCA | BRCA1/2, PIK3CA | DDR_bin, PI3K_bin |
| **Colorectal** | TCGA-COAD | KRAS, BRAF, MSI | MAPK_bin, IO_bin |
| **Pancreatic** | TCGA-PAAD | KRAS, SMAD4 | MAPK_bin |
| **Melanoma** | TCGA-SKCM | BRAF, NRAS | MAPK_bin |
| **Prostate** | TCGA-PRAD | BRCA2, PTEN | DDR_bin, PI3K_bin |

### **Expansion Strategy:**

1. **Reuse DDR_bin** - DNA repair features likely transfer across solid tumors
2. **Build pathway-specific bins** - MAPK_bin for KRAS-driven, IO_bin for TMB-high
3. **Cancer-agnostic pipeline** - Parameterize extraction by cancer type
4. **Incremental validation** - Each cancer needs its own head-to-head

---

## üõ†Ô∏è STEERABILITY ROADMAP

### **Steerability V0: PROXY Interventions (READY NOW)**

What we can do today:
- Clamp DDR gene count ‚Üí observe resistance risk delta
- Toggle NF1/DIS3 status ‚Üí observe drug ranking change
- "What-if" reasoning on validated markers

### **Steerability V1: DDR_bin Interventions (NEXT)**

What DDR_bin enables:
- Aggregate 9 TRUE SAE features into single intervention surface
- Clamp DDR_bin ‚Üí observe resistance risk change
- **Biological defense**: All 9 features are DDR-related

**Plumber Task:** Build `clamp_ddr_bin()` function that zeros DDR_bin features and re-runs classifier.

### **Steerability V2: Multi-Pathway Interventions (FUTURE)**

What pan-cancer expansion enables:
- MAPK_bin for KRAS-driven cancers
- PI3K_bin for PIK3CA-mutant cancers
- IO_bin for TMB-high/MSI-H cancers
- Combinatorial interventions: "What if DDR‚Üì AND MAPK‚Üë?"

---

## üéñÔ∏è THE 6 PILLARS (Updated Status)

### **Pillar 1: Tumor Burden** ‚úÖ STRONG

| Capability | Status |
|------------|--------|
| CA-125 tracking | ‚úÖ Production |
| CEA/PSA tracking | ‚úÖ Production |
| Trend analysis | ‚úÖ Production |

### **Pillar 2: Genomic Evolution** ‚úÖ BREAKTHROUGH

| Capability | Status | Evidence |
|------------|--------|----------|
| TRUE SAE features | ‚úÖ VALIDATED | AUROC 0.783 |
| DDR_bin pathway | ‚úÖ VALIDATED | p=0.0020 |
| PROXY SAE baseline | ‚úÖ PRODUCTION | AUROC 0.628 |
| Resistance prediction | ‚úÖ VALIDATED | DIS3 RR=2.08, NF1 RR=2.10 |
| Drug efficacy (S/P/E) | ‚úÖ PRODUCTION | 100% pathway alignment |
| Trial matching | ‚úÖ PRODUCTION | 0.92 mechanism fit |

### **Pillar 3: Immune Status** ‚úÖ GOOD

| Capability | Status |
|------------|--------|
| TMB calculation | ‚úÖ r=0.933 vs WES |
| MSI detection | ‚úÖ Production |
| HRD inference | ‚úÖ Production |
| IO eligibility | ‚úÖ Production |

### **Pillar 4: Metabolic State** ‚ùå NOT BUILT

Future work: PET-CT SUV tracking, metabolic inhibitor targeting.

### **Pillar 5: Microenvironment** ‚ùå NOT BUILT

Future work: VEGF, hypoxia markers, TIL analysis.

### **Pillar 6: Toxicity/Tolerance** ‚ö†Ô∏è PARTIAL

| Capability | Status |
|------------|--------|
| PGx toxicity | ‚úÖ Production |
| Toxicity-aware nutrition | ‚úÖ Production |
| Dose adjustment | ‚è≥ Not built |

---

## üìã PLUMBER ACTION ITEMS

### **P0: Verify Publication Package (TODAY)**

```bash
cd /Users/fahadkiani/Desktop/development/crispr-assistant-main
# Check figures exist
ls oncology-coPilot/oncology-backend-minimal/publication/figures/
# Expected: figure2_roc_curves.png, figure3_ddr_bin_distribution.png, figure4_feature_pathway_mapping.png

# Run validation suite
python3 oncology-coPilot/oncology-backend-minimal/scripts/validation/run_validations.py
```

### **P1: MM TRUE SAE Extraction (1-2 WEEKS)**

1. **Download MMRF data** from GDC (requires dbGaP access)
2. **Format mutations** like `tcga_ov_platinum_with_mutations.json`
3. **Run TRUE SAE extraction** using existing pipeline
4. **Head-to-head** TRUE SAE vs PROXY SAE for MM

### **P2: Build Steerability V1 (1 WEEK)**

1. **Create `clamp_ddr_bin()` function** - Zero out DDR_bin features
2. **Create `intervention_delta()` function** - Return change in resistance probability
3. **Add RUO banner** - "Research use only, counterfactual reasoning"
4. **Test on Ayesha's case** - Show DDR_bin intervention effect

### **P3: Pan-Cancer Pipeline (2-4 WEEKS)**

1. **Parameterize extraction script** by cancer type
2. **Download TCGA-LUAD, TCGA-BRCA, TCGA-COAD**
3. **Extract TRUE SAE** for each cancer
4. **Identify cancer-specific bins** (MAPK_bin for lung, etc.)

---

## üéØ SUCCESS METRICS

### **Publication (Immediate):**
- ‚úÖ TRUE SAE AUROC ‚â• 0.75 (achieved: 0.783)
- ‚úÖ Beats PROXY SAE (achieved: +0.155)
- ‚úÖ DDR_bin p < 0.05 (achieved: 0.0020)
- ‚è≥ bioRxiv preprint submitted

### **MM Expansion (Next):**
- ‚è≥ TRUE SAE AUROC ‚â• 0.70 for MM
- ‚è≥ Beats PROXY SAE (DIS3 RR=2.08 baseline)
- ‚è≥ Identifies MM-specific bins

### **Pan-Cancer (Future):**
- ‚è≥ At least 3 cancer types validated
- ‚è≥ Pathway bins transferable across cancers
- ‚è≥ Steerability V2 enables multi-pathway interventions

---

## üîó Related Documents

**Publication:**
- `oncology-coPilot/oncology-backend-minimal/publication/manuscript/MANUSCRIPT_DRAFT.md`
- `oncology-coPilot/oncology-backend-minimal/publication/figures/`

**SAE System:**
- `07_TRUE_SAE_DIAMONDS_EXCAVATION.md` - Diamond feature discovery
- `../SAE_FAILURE_POSTMORTEM.mdc` - What we learned from failures

**Resistance Prophet:**
- `../.cursor/rules/RESISTANCE_PROPHET_TO_MISSION_CONTROL_PLAN.mdc` - Full integration plan

---

*Document Owner: Zo*  
*Last Updated: December 23, 2025*  
*Status: ‚úÖ BREAKTHROUGH ACHIEVED - TRUE SAE VALIDATED*

